trending Market Intelligence /marketintelligence/en/news-insights/trending/Qs1G9l74Ax-MHN9PS-0RJQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lannett recalls 2 lots of seizure-treating drug due to microbial contamination

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Lannett recalls 2 lots of seizure-treating drug due to microbial contamination

Lannett Co. Inc. initiated a voluntary recall of two lots of its Levetiracetam Oral Solution due to microbial contamination.

Levetiracetam is indicated for treating partial-onset seizures in patients 1 month and older. It is also used as an add-on therapy in the treatment of different epilepsy patients, including patients aged 12 years and above with juvenile myoclonic epilepsy and patients aged 6 years and above with idiopathic generalized epilepsy.

Epilepsy is a central nervous system disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness.

The company issued the recall of the drug Dec. 18 after identifying the contamination of Bacillus subtilis during the evaluation of raw materials used to manufacture the medicine. Bacillus subtilis is bacteria that can lead to serious systematic infections, some of which have been reported by the company.

Previously in October, the Philadelphia-based company recalled all lots of its ranitidine syrup due to high levels of a potentially cancer-causing substance called N-Nitrosodimethylamine.